Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Leiomyomatosis

erlotinib hydrochloride has been researched along with Leiomyomatosis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Akhoundova, D; Choschzick, M; Helmchen, B; Hermanns, T; Hötker, AM; Mischo, A; Moch, H; Mühleisen, B; Rauch, A; Rupp, NJ; Valtcheva, N; Weber, A; Wyvekens, N1
Choi, JG; Choi, Y; Keam, B; Kim, D; Kim, M; Lee, JL; Park, I; Seo, JY; Yoon, S1
Go, H; Hong, BS; Lee, JL; Park, I; Shim, YS1

Other Studies

3 other study(ies) available for erlotinib hydrochloride and Leiomyomatosis

ArticleYear
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
    Genes, chromosomes & cancer, 2020, Volume: 59, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Erlotinib Hydrochloride; Female; Fumarate Hydratase; Humans; Leiomyomatosis; Middle Aged; Mutation, Missense; Neoplastic Syndromes, Hereditary; Skin Neoplasms; Uterine Neoplasms

2020
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
    Cancer research and treatment, 2019, Volume: 51, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Female; Fumarate Hydratase; Germ-Line Mutation; Humans; Kidney Neoplasms; Leiomyomatosis; Male; Middle Aged; Neoplastic Syndromes, Hereditary; Republic of Korea; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Uterine Neoplasms

2019
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
    BMC urology, 2019, Jun-10, Volume: 19, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Leiomyomatosis; Male; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Sirolimus; Skin Neoplasms; Time Factors; Treatment Failure; Uterine Neoplasms

2019